Patients with chronic myeloid leukemia (CML) relapsing in blast crisis after HLA-identical sibling bone marrow transplantation (BMT) are difficult to treat. Infusion of donor lymphocytes or retransplantation are unlikely to result in long-term disease-free survival. Treatment intensification with allogeneic double-BMT, made possible by using repeatedly mobilized peripheral blood stem cells, offers a new treatment option. We report two patients with Philadelphia chromosome positive CML transplanted in chronic phase, relapsing with CML in myeloid blast crisis. Both received intensive induction chemotherapy (ICE) followed by a first, T cell-depleted peripheral stem cell transplant from the initial donor. Both patients engrafted rapidly (day 15). Upon hematologic recovery, a second G-CSF mobilized non-T cell-depleted peripheral stem cell transplant from the same donor was given after pretransplant conditioning with busulphan and cyclophosphamide. Again, engraftment was rapid (days 18 and 16) and both patients are alive and disease-free 18 and 21 months after allogeneic double-BMT. G-CSF mobilized peripheral stem cells allow new ways of treatment intensification with double-BMT in refractory leukemias relapsing post-transplant. This approach warrants further study.
About 10-20% of patients with chronic myeloid leukemia (CML) in chronic phase relapse after HLA-identical sibling donor bone marrow transplantation (BMT). [1] [2] [3] [4] [5] Relapse probabilities are much higher for patients transplanted in accelerated phase or blast crisis. 6, 7 Response to infusion of donor lymphocytes is frequent in patients relapsing in chronic phase but rare when relapse presents with blast crisis CML. [8] [9] [10] Response to conventional chemotherapy is poor, with low rates of complete remission and short remission durations. 11, 12 Induction chemotherapy may cause prolonged aplasia. There is little information on how to appropriately treat patients transplanted in chronic phase and relapsing with blast crisis CML. Repeating an HLAidentical sibling transplant using the same donor has little effect. 13 In a report by the EBMT there were no long-term survivors.
14 Pretransplant conditioning regimens with higher drug or radiation doses have been previously shown to improve response in some patients with leukemia, but this was offset by increased toxicity. [15] [16] [17] Clearly, there is need for some form of treatment intensification. 18 We investigated allogeneic double-BMT as an approach to treatment intensification and report two patients with Philadelphia chromosome positive CML in blast crisis relapsed after HLA-identical sibling BMT. The first peripheral stem cell transplant was T cell-depleted and intended to accelerate hematologic recovery after conventional induction chemotherapy. In contrast, following hematologic recovery a second non-T cell-depleted transplant using pretransplant conditioning with busulphan and cyclophosphamide was given to establish a graft-versus-leukemia (GVL) effect.
Patients and methods

Protocol
After obtaining informed consent from patients and donors, ICE induction chemotherapy (idarubicin 8 mg/m 2 daily for 3 days; VP-16 100 mg/m 2 daily for 5 days; Ara-C 100 mg/m 2 twice daily for 10 days) was given with the double purpose of remission induction and pretransplant conditioning for the first transplant. Donor stem cells were mobilized with 10 g/kg of G-CSF for 5 days. Stem cells were harvested using a Cobe Spectra apheresis unit (Cobe, Lakewood, CO, USA) and 10-15 l of donor blood were processed to yield 3-4 × 10 6 CD34 + cells/kg. The apheresis product was T cell-depleted by a two-step procedure, magnetic bead positive CD34 selection (Isolex; Baxter, Deerfield, IL, USA) followed by anti-CD2 and anti-CD3 antibody-coated magnetic beads. The goal was to obtain a transplant with Ͼ2 × 10 6 CD34 + cells/kg and Ͻ1 × 10 5 T cells/kg. The peripheral stem cells were infused without prior cryopreservation 2 days after the last Ara-C dose. Engraftment was defined as an increase to у0.5 × 10 9 /l neutrophils for 3 consecutive days. Immediately after stable engraftment a conventional conditioning regimen with busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) was given followed by a second non-T cell-depleted peripheral stem cell transplant from the same donor. Again, donor stem cells were mobilized with 10 g/kg of G-CSF for 5 days and given without further manipulation. Graft-versushost disease (GVHD) prophylaxis was with cyclosporine for 3 months.
Case 1
A 24-year-old female patient was diagnosed in February 1991 with Philadelphia chromosome positive CML in first chronic phase. She underwent non-T cell-depleted bone marrow transplantation from her HLA-identical sister 2 months after diagnosis. Pretransplant conditioning consisted of cyclophosphamide (120 mg/kg), etoposide (30 mg/kg) and TBI (12 Gy in six fractions over 3 days). GVHD prophylaxis was with short course methotrexate and cyclosporine. The transplant course was uneventful; she developed grade I acute GVHD and no chronic GVHD. She returned to a fully active personal and professional life.
Five years after BMT, relapse of CML in myeloid blast crisis was diagnosed. She presented with symptoms of protracted pharyngitis and Ͼ50% myelomonocytic blast cells were found in the marrow and peripheral blood, staining positively for myeloperoxidase and expressing CD34, CD33 and CD11b. Cytogenetic studies were positive for the Philadelphia chromosome and multiple additional chromosomal abnormalities (t(12;13), Ϫ12, +3r, +8, +21, der(13)).
Case 2
A 40-year-old male patient was diagnosed in October 1986 with Philadelphia chromosome positive CML in first chronic phase. He was treated with busulphan and hydroxyurea for 1 year and underwent a bone marrow transplant, T cell-depleted using counterflow elutriation, from his HLAidentical sister in October 1987. Pretransplant conditioning consisted of cyclophosphamide (120 mg/kg) and TBI (12 Gy in six fractions). He did not develop clinically significant GVHD and relapsed in October 1989 with chronic phase CML. He underwent a second BMT from the same donor in May 1990 with busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) conditioning and GVHD prophylaxis with cyclosporin A and short course methotrexate. In February 1996, 8 years after the initial and 6 years after the second transplant he relapsed again with Philadelphia chromosome positive CML in myeloid blast crisis. The marrow contained Ͼ60% of myeloperoxidase-positive blast cells, expressing CD34, CD33, CD13 and CD7.
Both patients underwent allogeneic double-BMT as specified in the protocol section.
Results
Details on stem cell harvest and processing, stem cell dose, engraftment, response to treatment and follow-up are listed in Table 1 and Figure 1 . Donors were mobilized twice successfully within a 1-2 month period and engraftment was rapid and complete twice in both patients. Limited toxicities were observed post-transplant and both patients are alive and well, 1. and 2 years post-double transplant procedure in complete hematologic and cytogenetic remission with molecular evidence of residual disease in one patient.
Discussion
We describe two patients with CML in blast crisis relapsed after HLA-identical sibling BMT and successfully treated on a new protocol of allogeneic peripheral stem cell double-BMT. Double transplants have been used successfully in autologous BMT and there are data suggesting a superior effect as compared to single transplants in patients with multiple myeloma and possibly solid tumors. [19] [20] [21] The possible advantage of double-BMT is the added antitumor effect. Stem cell rescue between transplants accelerates hematologic recovery and allows for early repetitive treatment and thus increased treatment intensity. It is likely that double-BMT also increases the overall toxicity of treatment and it remains to be determined what patient groups, if any, will have long-term benefit from double-BMT. The antitumor effect of allogeneic BMT is due to the combined action of cytotoxic treatment and the GVL effect. 22 In allogeneic double-BMT two problems arise: (1) the pretransplant conditioning of the second transplant abrogates the GVL effect of the first transplant, which somehow contradicts the rationale of the procedure; and (2) the limited availability of donor bone marrow stem cells. The latter problem may be solved by using mobilized peripheral blood stem cells. Either peripheral stem cells are harvested in sufficient number for two transplants or peripheral stem cells are mobilized twice with G-CSF; 23 this may be more acceptable to the donor than harvesting bone marrow more than once in a short period.
After induction chemotherapy with ICE, which served the double purpose of induction treatment and pretransplant conditioning for the first transplant, T cell-depleted allogeneic stem cell support was provided to shorten duration of aplasia and thus to decrease treatment-related morbidity. No GVL effect was intended at this point and GVHD was to be avoided. In the two cases reported, the first transplant led to rapid hematologic recovery without GVHD and allowed immediate progression with the second transplant.
Rapid engraftment occurred after the first transplant in spite of a nonmyeloablative conditioning regimen. It is likely that residual chimerism, ie the presence of some residual donor hemopoiesis at the time of the first transplant, contributed to this engraftment and it is therefore unknown whether these results can be extrapolated to patients who have not undergone previous transplantation. Allogeneic 'mini'-transplants have been reported recently in elderly patients with malignant disease, who have engrafted without myeloablative chemo-/radiation treatment. 24 Unfortunately, although we do not have chimerism data available on hemopoiesis between the two transplants, the rapid hematologic regeneration is in favor of donor engraftment.
In contrast, the second transplant was designed to deliver a GVL effect. Consequently the second peripheral stem cell CFU-GM = colony-forming units granulocyte/macrophage; STR = short tandem repeats polymorphism. transplant was not T cell-depleted. Mild chronic GVHD and disease-free survival of 18 and 21 months in these two patients are compatible with such an effect. This treatment strategy will test the hypotheses of whether sufficient numbers of peripheral stem cells can be serially mobilized with G-CSF in the same donor within a relatively short time period, whether there is short-term engraftment with a CD34 + -enriched and T cell-poor stem cell product, whether there is an additional antitumor effect, and whether toxicity of such a strategy is acceptable. In order to answer these questions large numbers of patients will have to be treated on such protocols.
It is our hope that allogeneic double-BMT, by uniquely combining intensified chemotherapy with the immunotherapy of allogeneic BMT will result in more effective treatment of post-transplant relapse without patients being lost to increased toxicity.
